Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure
Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »